Last reviewed · How we verify
NCT06842121
A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)
Phase 1 trial testing Sodium Glycerophosphate Injection in Parenteral Nutrition in 42 participants. Completed in 22 May 2025.
22 May 2025
Quick facts
| Lead sponsor | Baxter Healthcare Corporation |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 42 |
| Start date | 27 January 2025 |
| Primary completion | 22 May 2025 |
| Estimated completion | 22 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Sodium Glycerophosphate Injection — full drug profile →
- Sodium Phosphates Injection — full drug profile →
Conditions studied
- Parenteral Nutrition — all drugs for Parenteral Nutrition →
Sponsor
Baxter Healthcare Corporation — full company profile →
Who can join
Adults 18 to 55, any sex, with Parenteral Nutrition. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase 1, prospective, single-center, randomized sequence, double-blind, 2-way crossover, relative bioavailability study in healthy adult subjects comparing Sodium Glycerophosphate Injection (SGP) to Sodium Phosphate Injection (NaP). In this study it is planned to randomize approximately 42 healthy male and female subjects. All study periods will be completed during a single residency, the overall duration of residency will be 11 days (10 nights).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06842121
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sodium Glycerophosphate Injection
Trials testing the same drug.
- NCT06842134 — A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E · Phase 1 · completed
Other recruiting trials for Parenteral Nutrition
Currently open trials in the same condition.
- NCT06625957 — Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition · Phase 3 · recruiting
- NCT06510348 — Achieving nuTritional Target in criticAlly Ill patieNts With iMpairEd gastroiNtesTinal Dysfunction · NA · recruiting
- NCT06525753 — Weaning is Winning? (WeWin Study) · recruiting
Other Baxter Healthcare Corporation trials
Trials by the same sponsor.
- NCT07256951 — Gen 2 Battrode Wear Study · NA · recruiting
- NCT07158333 — Mobile Cardiac Telemetry (MCT) Study · completed
- NCT06842134 — A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E · Phase 1 · completed
- NCT05996809 — PMCF Study for COSEAL® in Gynecologic Surgery · completed
- NCT06056011 — Timmy3 Module Clinical Accuracy ISO 80601-2-56:2017 + A1 2018 · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06842121 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baxter Healthcare Corporation
- Last refreshed: 29 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06842121.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing